Close Menu

HTG Molecular HTG EdgeSeq Autoimmune Panel

Oct 15, 2019

HTG Molecular said it is now taking orders for its new HTG EdgeSeq Autoimmune Panel, which it expects to commercially launch in kit form or as a service at the end of October. The firm said it has designed the panel to address questions around autoimmune disorders, as well as for examining immune system dysfunction, discovering new biomarkers, and discovering predictive signatures of drug responses in the autoimmune space. 

More Like This

Jan 14, 2020

Congenica Neuro

Congenica has introduced Congenica Neuro, a module for the company's clinical decision support platform to help physicians characterize epilepsy and neurodevelopmental disorders. The technology automates prioritization of genetic variants and helps accelerate the identification, review, and reporting of de novo variants by comparing test results to curated gene panels and preconfigured filters, the company said. 

Jan 14, 2020

Biocept Target Selector for CSF

Biocept's Target Selector liquid biopsy assays are now available to physicians to evaluate patients' cerebrospinal fluid for the presence of circulating tumor cells and biomarkers for patients with breast or lung cancer suspected of brain or central nervous system metastases. The presences of such cells may indicate brain metastases. Biocept said that up to 30 percent of patients with breast cancer and up to 36 percent of patients with ung cancer will develop brain metastases.  

Jan 14, 2020

Oxford Gene Technology: SureSeq CLL + CNV Panel

Oxford Gene Technology has launched the SureSeq CLL + CNV Panel for cancer research. The next-generation sequencing assay has been designed in collaboration with cancer experts to detect 12 key genes and five chromosomal regions implicated in chronic lymphocytic leukemia (CLL) progression.

The panel alleviates the burden of running multiple assays and delivers a comprehensive genomic profile for each CLL sample using a single workflow. It can identify loss of heterozygosity, copy number variation with a size range of a single exon to the whole gene, loss of chromosomal arms, and whole chromosome gains in trisomy 12.

It comes with complimentary data analysis software.

Jan 14, 2020

Genome Diagnostics NGSengine

Genome Diagnostics has released a new version of its NGSengine human leukocyte antigen typing software. The updated NGSengine is now capable of exporting HLA typing results of individual samples directly to the Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) matching-services website, thanks to a recent partnership between Netherlands-based GenDx and German firm PIRCHE. This, the company said, will give laboratories the ability to predict indirectly recognizable HLA epitopes for either hematopoietic stem cells or solid organs.

Jan 13, 2020

Bio-Rad Laboratories: SEQuoia

Bio-Rad Laboratories announced the launch of the SEQuoia Complete Stranded RNA Library Prep Kit for RNA-Seq library preparation. The kit uses SEQzyme, an enzyme that couples cDNA synthesis with adapter addition in a continuous synthesis reaction. It is compatible with a broad range of sample inputs and allows capture of the complete transcriptome, including short and long RNAs, in a single library prep. The kit generates cDNA libraries suitable for strand-specific next-generation sequencing on Illumina sequencers in less than 4 hours. It also includes access to the integrated SeqSense analysis solution to process and quality control sequencing data for all RNA biotypes in the library within a single analysis pipeline.

Jan 13, 2020

OncoCyte DetermaRx

OncoCyte has launched the DetermaRx, test for identifying early-stage lung cancer patients who may benefit from adjuvant chemotherapy after surgical resection. The test was formerly known as the Razor treatment stratification test and was being developed by Razor Genomics, which OncoCyte acquired in September. Regulators in Canada have approved the test for marketing in that country, the Irvine, California-based firm said. In the US, Florida Precision Oncology and the Leonard Cancer Institute at Mission Hospital in Mission Viejo, California have signed up as early access users of the test, OncoCyte said. It said that in a clinical study, high-risk patients identified by the test post-surgery and treated with adjuvant chemotherapy had a "significant" increase in survival rates. 

Jan 13, 2020

Dovetail Genomics: Genome Assembly Services With Omni-C

Dovetail Genomics has launched an expanded menu of genome assembly services, including 3D genome conformation analysis, annotations, and chromosome-scale assemblies.

The services leverage the firm's Omni-C technology, which provides improved scaffolding, SNP detection, and haplotype phasing.

Jan 09, 2020

Qiagen QiaSymphony PowerFecal Pro DNA Kit

Qiagen has launched the QiaSymphony PowerFecal Pro DNA Kit for the isolation of microbial genomic DNA from stool and soil using the QiaSymphony automation platform. The new kit enables automated, time-saving, standardized extraction of inhibitor-free DNA from stool and soil samples for metagenomic analysis, and is designed for 192 samples with continuous loading of 24-sample batches. Qiagen said that its new PowerBead Pro tubes are included in the kit for homogenization. The beads and optimized chemistry enable more efficient lysis of bacteria and fungi.

Jan 09, 2020

Pillar Biosciences Onco/Reveal Solid Tumor Panel

Pillar Biosciences has launched the Pillar Onco/Reveal Solid Tumor Panel, a 47-gene enrichment assay for research use. The panel leverages Pillar's SLIMamp enrichment chemistry, which uses primers that are designed to form stem loops to suppress unwanted amplicons during PCR amplification, enabling multiplexed NGS library preparation in a single tube. The test was licensed from Columbia University and recently received approval from the New York State Department of Health.

Jan 09, 2020

Personalis NeXT Dx Test

Personalis has launchedthe NeXT Dx Test, a next-generation sequencing panel designed to help oncologists identify potential therapies and clinical trial options for cancer patients. The assay analyzes approximately 20,000 genes in both the tumor exome and transcriptome, and includes advanced analytics to provide a diagnostic report on genetic alterations in medically important cancer genes, as well as emerging immunotherapy-related biomarkers such as microsatellite instability status and tumor mutational burden.

Jan 08, 2020

Viracor Eurofins 'Viracor TRAC'

Viracor Eurofins has begun offering its Viracor TRAC donor-derived, cell-free DNA assay for diagnosing kidney transplant rejection. The noninvasive liquid biopsy test has similar characteristics to other donor-derived cfDNA assays on the market, Viracor Eurofins said. Two ongoing prospective and one retrospective clinical trials are underway to further develop clinical data to support use of the test. The current gold standard for diagnosing kidney transplant rejection and surveillance is organ biopsy, which is both expensive and can lead to multiple complications for the patient, the firm noted. 

Jan 07, 2020

PreventionGenetics Rapid PGxome WES Test

PreventionGenetics has added the Rapid PGxome whole-exome sequencing test to its clinical testing menu. It is ideal for situations where a rapid genetic diagnosis is essential, including patients with neonatal, infantile,  or early childhood onset severe disorders, the company noted. Rapid PGxome starts at $2,290 per test and must be ordered by a qualified healthcare provider. It has a turnaround time of 14 days and, in cases with a clear positive result, a preliminary report may be issued in as few as six days.

Jan 06, 2020

Sysmex Ipsogen JAK2 DX

Sysmex has launched the ipsogen JAK2 DX reagent after the product received health insurance coverage in Japan on Jan. 1. The Kobe, Japan-based firm said that it received marketing approval for the gene testing kit that measures the JAK2V617F mutation quantitatively in December 2018. The test is used to diagnose certain hematopoietic tumors, specifically polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Sysmex inked a distribution deal with Ipsogen (now part of Qiagen) in 2011 covering Japan that allows Sysmex to distribute some Ipsogen blood cancer products in that country.

Jan 02, 2020

AMS Biotechnology cfPure Max Cell-Free DNA Purification Kit

AMS Biotechnology has released the cfPure Max kit for circulating cell-free DNA purification. It is designed for samples with a volume of at least 5 ml. The company's cfPure kits use silica-coated paramagnetic particles to purify cell-free DNA from less than 1 ml to more than 10 ml of serum or plasma, for downstream applications such as bisulfite sequencing, next-generation sequencing, or qPCR.

Dec 19, 2019

Lucid Diagnostics EsoGuard Esophageal DNA Test

PAVmed's Lucid Diagnostics subsidiary has launched its EsoGuard Esophageal DNA Test as a laboratory-developed test after completing CLIA/CAP certification of the test. EsoGuard is a DNA test designed to facilitate the diagnosis of Barrett's esophagus and related precursors to esophageal adenocarcinoma.

EsoGuard LDT is performed on cells which are noninvasively sampled from the distal esophageal lining and shipped in a custom preservative solution to the ResearchDx facility in Irvine, California, where the DNA is immediately extracted. The DNA is then subjected to bisulfite conversion, PCR amplification, and next-generation sequencing to determine the methylation status of 31 sites on the vimentin and cyclinA1 genes, the company said. A bioinformatic algorithm is used to calculate the percentage of DNA molecules in which a proportion of methylated sites on either gene exceeds a certain threshold, delivering a positive or negative result.

A positive result has been associated with the presence of non-dysplastic Barrett's esophagus, dysplastic Barrett's esophagus, or esophageal adenocarcinoma, PAVmed added.

Bloomberg Law writes that the Genetic Information Nondiscrimination Act may work better as a privacy, rather than anti-discrimination, law.

A new report finds that though the US has increased its activity in science and engineering, its global share of that activity has fallen in some areas, according to Inside Higher Ed.

TechCrunch reports that Linda Avey has a new personal genomics startup that's focusing on India.

In Nature this week: genomic analysis of rapeseed, universal target enrichment method for metagenomic sequencing, and more.